title: Stent-oriented versus patient-oriented outcome in patients undergoing early percutaneous coronary intervention for acute coronary syndrome: 2-year report from the BASE-ACS trial.
abstract: BACKGROUND
  The BASE-ACS trial demonstrated an outcome of the titanium-nitride-oxide-coated bioactive stents (BAS) statistically non-inferior to that of the everolimus-eluting stents (EES) at 12-month follow-up in patients presenting with acute coronary syndrome (ACS). We performed a post hoc analysis of the BASE-ACS trial with particular focus on stent-oriented versus patient-oriented outcome at 24-month follow-up.
  
  
  METHODS
  A total of 827 patients with ACS were randomly assigned to receive either BAS (417) or EES (410). Stent-oriented outcome was defined as a composite of cardiac death, target vessel-related non-fatal myocardial infarction, or ischemia-driven target lesion revascularization. Patient-oriented outcome was defined as a composite of all-cause death, any non-fatal myocardial infarction, or any revascularization.
  
  
  RESULTS
  Clinical follow-up for 24 months was completed in 406 (97.4%) patients in the BAS group and in 398 (97.1%) in the EES group. Stent-oriented outcome at 24-month follow-up occurred at similar frequencies in the two stent groups (10.1% for BAS versus 11.2% for EES, P=0.53). Likewise, patient-oriented outcome at 24-month follow-up was similar in the two groups (16.3% versus 19.8%, respectively, P=0.2).
  
  
  CONCLUSIONS
  In patients presenting with ACS, the rates of both stent-oriented and patient-oriented outcomes at 24-month follow-up in the BAS group were similar to those in the EES group.
authors.affiliation: Department of Internal Medicine, Division of Cardiology, University of Oulu , Oulu , Finland.
authors.forename: Hannu
authors.initials: H
authors.lastname: Romppanen
authors.forename: Wail
authors.initials: W
authors.lastname: Nammas
authors.forename: Kari
authors.initials: K
authors.lastname: Kervinen
authors.forename: Juhani K E
authors.initials: JK
authors.lastname: Airaksinen
authors.forename: Mikko
authors.initials: M
authors.lastname: Pietilä
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivero-Crespo
authors.forename: Adam
authors.initials: A
authors.lastname: Debelder
authors.forename: Pintoko
authors.initials: P
authors.lastname: Tedjokusumo
authors.forename: Jussi
authors.initials: J
authors.lastname: Mikkelsson
authors.forename: Antti
authors.initials: A
authors.lastname: Ylitalo
authors.forename: Pasi P
authors.initials: PP
authors.lastname: Karjalainen
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D017202:Myocardial Ischemia / Q000453:epidemiology; D063868:Patient Outcome Assessment; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011446:Prospective Studies; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D015607:Stents; D014025:Titanium / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: C434243:titanium-nitride-oxide; D000068338:Everolimus; D014025:Titanium; D020123:Sirolimus